124 related articles for article (PubMed ID: 8635161)
1. Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers.
Okajima E; Fukuda T; Okita S; Tsutsumi M; Hirao Y; Okajima E; Konishi Y
Cancer Lett; 1996 Jun; 103(2):227-31. PubMed ID: 8635161
[TBL] [Abstract][Full Text] [Related]
2. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence.
Friedrich MG; Blind C; Milde-Langosch K; Erbersdobler A; Conrad S; Löning T; Hammerer P; Huland H
Eur Urol; 2001 Nov; 40(5):518-24. PubMed ID: 11752859
[TBL] [Abstract][Full Text] [Related]
3. Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas.
Kai M; Arakawa H; Sugimoto Y; Murata Y; Ogawa M; Nakamura Y
Jpn J Cancer Res; 1995 Mar; 86(3):249-51. PubMed ID: 7744694
[TBL] [Abstract][Full Text] [Related]
4. Deletion of the p16 and p15 genes in human bladder tumors.
Orlow I; Lacombe L; Hannon GJ; Serrano M; Pellicer I; Dalbagni G; Reuter VE; Zhang ZF; Beach D; Cordon-Cardo C
J Natl Cancer Inst; 1995 Oct; 87(20):1524-9. PubMed ID: 7563186
[TBL] [Abstract][Full Text] [Related]
5. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.
Miyamoto H; Kubota Y; Fujinami K; Dobashi Y; Kondo K; Yao M; Shuin T; Hosaka M
Oncol Res; 1995; 7(7-8):327-30. PubMed ID: 8747595
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas.
Asamoto M; Iwahori Y; Okamura T; Shirai T; Tsuda H
Jpn J Clin Oncol; 1997 Feb; 27(1):22-5. PubMed ID: 9070336
[TBL] [Abstract][Full Text] [Related]
7. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
Gruis NA; Weaver-Feldhaus J; Liu Q; Frye C; Eeles R; Orlow I; Lacombe L; Ponce-Castaneda V; Lianes P; Latres E
Am J Pathol; 1995 May; 146(5):1199-206. PubMed ID: 7747814
[TBL] [Abstract][Full Text] [Related]
8. Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9.
Wu Q; Possati L; Montesi M; Gualandi F; Rimessi P; Morelli C; Trabanelli C; Barbanti-Brodano G
Int J Cancer; 1996 Mar; 65(6):840-6. PubMed ID: 8631601
[TBL] [Abstract][Full Text] [Related]
9. Increased p16 levels correlate with pRb alterations in human urothelial cells.
Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C
Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615
[TBL] [Abstract][Full Text] [Related]
10. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
Williamson MP; Elder PA; Shaw ME; Devlin J; Knowles MA
Hum Mol Genet; 1995 Sep; 4(9):1569-77. PubMed ID: 8541841
[TBL] [Abstract][Full Text] [Related]
11. Absence of p16/MTS1 gene mutations in human prostate cancer.
Chen W; Weghorst CM; Sabourin CL; Wang Y; Wang D; Bostwick DG; Stoner GD
Carcinogenesis; 1996 Dec; 17(12):2603-7. PubMed ID: 9006095
[TBL] [Abstract][Full Text] [Related]
12. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
[TBL] [Abstract][Full Text] [Related]
13. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
14. Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
Southgate J; Proffitt J; Roberts P; Smith B; Selby P
Br J Cancer; 1995 Nov; 72(5):1214-8. PubMed ID: 7577470
[TBL] [Abstract][Full Text] [Related]
15. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
16. p53 gene mutation in recurrent superficial bladder cancer.
Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
[TBL] [Abstract][Full Text] [Related]
17. [The study of p53 gene mutation in human bladder cancer].
Ding Q; Zhang Y; Sun X
Zhonghua Wai Ke Za Zhi; 1995 Nov; 33(11):684-6. PubMed ID: 8731915
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers.
Shimizu T; Sekiya T
Int J Cancer; 1995 Nov; 63(5):616-20. PubMed ID: 7591275
[TBL] [Abstract][Full Text] [Related]
19. Deletion of p16 and p15 genes In schistosomiasis-associated bladder cancer (SABC).
Eissa S; Ali-Labib R; Khalifa A
Clin Chim Acta; 2000 Oct; 300(1-2):159-69. PubMed ID: 10958872
[TBL] [Abstract][Full Text] [Related]
20. No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas.
Sun Y; Hildesheim A; Lanier AE; Cao Y; Yao KT; Raab-Traub N; Yang CS
Oncogene; 1995 Feb; 10(4):785-8. PubMed ID: 7862458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
